Business
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors, effective February 7, and a newly formed Executive Committee of the Board consisting of Dr. Sandrock, Michael Higgins, interim chief executive officer and Board Chairman, and Glenn Pierce, M.D., Ph.D., interim chief scientific officer and Board member. Dr. Sandrock will work with Voyager leadership to help shape future strategies for the Company’s next-generation TRACERTM AAV capsid screening platform and therapeutic programs, and expand its external collaborations with scientific leaders and industry partners. The Company also announced the promotion of Robin Swartz to chief operating officer, effective February 7. As a component of this new role, Ms. Swartz will join the full leadership team in working closely with the Executive Committee, while overseeing Portfolio and Partner Management, IT, Finance, Communications, and Quality and Technology Operations. “We are thrilled to welcome Al Sandrock to Voyager. Al is a scientific visionary who led the development of multiple transformational therapies for serious neurological diseases. The Voyager leadership team looks forward to working closely with Al as he helps to inform long-term strategies for the Company’s TRACER™ AAV capsid platform, therapeutic programs, and external collaborations,” said Mr. Higgins. “Voyager has made important advances in identifying unique AAV capsids that have demonstrated strong potential to maximize efficacy in target tissues, and minimize off target toxicities associated with first-generation approaches. With industry-leading technology and a talented team, we are well positioned to harness the full potential of our TRACER platform with the goal of delivering breakthrough therapies to patients. Further, I am very pleased to announce the promotion of Robin Swartz to chief operating officer. Robin is a proven and respected leader whose passion for patients is reflected in her deep c...